summari
introduct
interferon
ifn
act
slowli
arrest
acut
viral
infect
interferona
ifna
prepar
prove
use
chronic
infect
clearli
use
increasingli
futur
prepar
deriv
human
leucocyt
cultur
b
lymphoblastoid
cell
routin
clinic
use
mixtur
number
distinct
subtyp
human
ifna
identifi
also
slightli
differ
version
singl
subtyp
made
recombin
dna
procedur
bacteria
ifna
prepar
inject
intramuscularli
subcutan
doserel
side
effect
common
usual
toler
prolong
treatment
may
caus
increas
fatigu
depress
patient
form
neutralis
antibod
i
block
effect
ifn
appear
rel
common
recombin
ifn
deriv
human
cell
given
intranas
ifna
prevent
subsequ
experiment
rhinoviru
infect
interferon
ifn
antivir
protein
play
import
role
natur
control
viral
infect
gresser
et
al
b
classifi
w
type
chemicallyrel
antigen
distinct
variant
form
cell
anim
speci
human
interferon
huifn
form
human
cell
natur
life
cultur
respons
variou
stimuli
especi
viral
infect
least
subtyp
huifna
amino
acid
common
differ
least
biolog
properti
finter
singl
huifn
mani
properti
ifna
share
amino
acid
cytokin
term
ifn
classifi
one
huifnw
amino
acid
chemic
close
relat
ifna
antigen
quit
distinct
yet
separ
test
patient
ifn
formerli
term
type
immun
ifn
cell
iymphokin
differ
ifn
chemic
structur
properti
thu
far
littl
use
viral
infect
review
howev
mainli
consid
result
obtain
prepar
ifna
develop
ifn
clinic
use
review
billiau
year
previou
research
viru
interfer
phenomenon
henl
potenti
valu
ifn
antivir
agent
use
patient
realis
soon
discov
isaac
lindenmann
howev
suffici
amount
ifn
allow
clinic
evalu
becam
avail
nearli
use
trial
cancer
patient
inde
ifn
far
use
mainli
manag
form
ofleukaemia
type
cancer
increasingli
use
treat
chronic
viral
infect
discuss
review
ifna
bind
specif
receptor
cell
surfac
result
intracellular
process
still
elucid
ifnstimul
respons
element
isr
cell
nucleu
activ
number
protein
synthesis
includ
mx
protein
human
analogu
weitz
et
al
specif
antivir
function
enzym
synthetas
synthetas
protein
kinas
probabl
produc
gener
resist
treat
cell
viral
infect
hovanessian
pestka
et
al
antivir
state
reach
peak
hour
cell
first
expos
ifn
establish
may
persist
though
slowli
wane
mani
hour
tabl
make
ifn
amount
suffici
clinic
use
requir
human
cell
act
sourc
number
initi
seem
almost
imposs
larg
first
solut
use
white
blood
cell
obtain
byproduct
freshli
donat
transfus
blood
strander
cantel
treat
mous
parainfluenza
viru
sendai
form
term
leucocyt
ifn
fig
partial
purif
product
use
almost
clinic
studi
leucocyt
ifn
rel
expens
difficult
make
control
even
cell
mani
thousand
individu
blood
donat
yield
suffici
ifn
treat
patient
time
anoth
system
devis
wellcom
research
laboratori
beckenham
use
commerci
scale
product
human
cell
johnston
cell
immortalis
human
lymphoblastoid
line
namalwa
grown
larg
stainless
steel
tank
stimul
sendai
viru
secret
mani
differ
ifna
subtyp
separ
medium
highli
purifi
final
product
wellferon
essenti
pure
mixtur
least
subtyp
namalwa
cell
origin
burkitt
tumour
biopsi
rigor
safeti
cell
igin
antivir
effect
establish
sever
hour
thu
administr
interferon
unlik
use
acut
viral
infect
valuabl
chronic
infect
natur
antivir
defenc
mechan
activ
hour
contrast
onset
activ
immun
sever
day
nonimmun
host
specif
particular
virus
effect
extracellular
viru
particl
mechan
involv
activ
respons
cell
interferon
molecul
bind
specif
surfac
receptor
sever
protein
synthesis
includ
antivir
prote
in
mx
analogu
enzym
protein
kinas
oligoadenyl
synthetas
degrad
newli
form
viral
compon
test
new
type
devis
appli
fintcr
fant
finter
et
al
lymphoblastoid
ifn
licens
clinic
trial
use
nation
control
author
uk
usa
japan
subsequ
sale
treatment
specifi
diseas
sever
countri
first
medicin
product
manufactur
transform
cell
line
exampl
greatli
facilit
accept
cell
manufactur
import
therapeut
protein
factor
viii
granulocyt
macrophag
coloni
stimul
factor
gmcsf
group
independ
use
recombin
dna
procedur
obtain
express
human
ifna
gene
transfect
escherichia
coli
goeddel
et
al
nagata
et
al
rout
use
manufactur
commerci
product
particular
version
subtyp
human
ifn
roferon
roch
intron
schere
berefor
boehringeringelheim
fig
differ
singl
amino
acid
recombin
prepar
also
wide
licens
use
differ
intern
standard
leucocyt
lymphoblastoid
recombin
ifn
emphasis
fact
ideo
et
al
patient
treat
ifna
prepar
period
mani
month
proport
develop
neutralis
antibodi
present
high
concentr
may
block
effect
ifn
loss
clinic
benefit
treatment
antibodi
seem
frequent
ifna
prepar
other
caus
clinic
problem
treatment
variou
cancer
viral
infect
probabl
latter
treatment
cours
usual
relativel
much
shorter
antonel
et
al
examin
sera
rel
homogen
group
chronic
hepat
patient
found
antibodi
neutralis
ifn
sera
treat
treat
treat
iymphoblastoid
ifn
neutralis
antibodi
also
observ
chines
children
chronic
hepat
b
treat
recombin
higher
titr
drug
less
like
respond
treatment
incid
titr
low
lok
et
al
lok
lai
oberg
use
ifn
treat
patient
malign
carcinoid
tumour
present
hannov
interferon
workshop
februari
neutralis
antibodi
develop
associ
clinic
relaps
treat
treat
recombin
none
treat
leucocyt
ifn
relaps
patient
switch
treatment
leucocyt
ifn
half
achiev
respons
similar
problem
recombin
seen
chronic
myelogen
leukaemia
von
wussow
et
al
von
wussow
et
al
hairi
cell
leukaemia
stei
et
al
essenti
mix
cryoglobulinaemia
casato
et
al
essenti
thrombocythaemia
gugliotta
et
al
mani
patient
success
retreat
human
cellderiv
ifn
prepar
ifna
prepar
given
intramuscular
subcutan
inject
intraven
rout
seem
advantag
ifna
potent
even
larg
dose
megaunit
mu
intern
unit
human
ifna
requir
ifn
protein
provid
complet
cours
patient
chronic
hepat
treatment
ifna
accompani
influenzalik
side
effect
fever
almost
invari
first
dose
usual
diminish
subsequ
dose
rel
common
side
effect
includ
lassitud
fatigu
depress
leucopenia
thrombocytopenia
elev
liver
enzym
effect
dose
relat
least
rang
iomu
vari
greatli
sever
one
individu
anoth
patient
intoler
even
small
dose
wherea
other
accept
rel
larg
amount
without
difficulti
inject
given
even
side
effect
occur
mainli
hour
sleep
howev
prolong
cours
may
progress
increas
fatigu
depress
sometim
limit
durat
ifn
treatment
ifn
prove
effect
acut
viral
infect
common
cold
part
may
antivir
respons
slow
come
effect
much
import
factor
treatment
like
late
patient
acut
viral
infect
influenza
feel
ill
mani
million
cell
alreadi
infect
accordingli
form
releas
quota
ifn
inject
still
unlik
help
contrast
ifn
use
success
proph
ylaxi
treatment
certain
chronic
viral
infect
latter
number
cell
infect
form
ifn
one
time
like
small
suppli
addit
amount
benefici
tabl
ii
sinc
earlier
inform
use
ifn
viral
infect
consid
detail
elsewher
scott
tyrrel
review
concentr
recent
result
wellcontrol
studi
healthi
volunt
shown
intra
nasal
administ
ifna
suppress
symptom
follow
experiment
infect
rhinoviru
judg
object
criteria
review
scott
tyrel
quarter
volunt
given
ifn
nevertheless
shed
viru
nasal
secret
even
though
minim
symptom
human
ifna
prepar
type
approxim
activ
rhinovirus
ifn
slightli
less
activ
weightforweight
basi
higgin
et
al
ifni
complet
inact
higgin
et
al
ifna
also
protect
volunt
experiment
infect
coronaviru
though
much
less
effici
influenza
viru
phillpott
et
al
littl
publish
recent
method
deliv
ifn
respiratori
tract
although
usual
appli
form
intranas
ifn
spray
mix
particl
size
deliv
fine
nozzl
selfactu
pump
nevertheless
comparison
show
administr
nasal
drop
result
favour
distribut
radiolabel
albumin
hard
palat
aoki
crawley
time
dose
ifna
relat
rhinoviru
challeng
seem
critic
outcom
phillpott
et
al
unless
ifn
given
within
hour
challeng
protect
result
irrespect
much
given
previou
day
ifn
induc
longliv
antivir
state
nasal
epitheli
cell
cultur
surpris
suggest
mechan
straightforward
protect
cell
rhinoviru
may
oper
vivo
minimum
effect
dose
given
samo
et
al
prefer
time
phillpott
et
al
per
day
singl
larger
daili
dose
lomu
slightli
effect
reduc
symptom
viru
shed
hayden
gwaltney
samo
et
al
scott
et
al
protect
studi
rhino
virus
ifna
administr
continu
day
viru
challeng
ifna
given
symptom
cold
start
minor
effect
viru
shed
cours
cold
chang
hayden
gwaltney
intranas
ifn
caus
system
symptom
lead
local
inflamm
day
regular
use
histolog
mucosa
ulcer
fill
lymphocyt
helper
phenotyp
hayden
et
al
one
studi
half
volunt
stop
take
ifn
fourteenth
day
dose
symptom
similar
though
retrospect
distinguish
proven
rhinoviru
infect
suffer
subject
placebo
group
mild
leucopenia
observ
patient
take
intranas
ifna
extent
dose
relat
associ
occurr
nasal
symptom
local
advers
effect
long
term
administr
ifna
practic
way
provid
prophylaxi
cold
particular
season
altern
strategi
would
healthi
subject
treat
limit
period
high
risk
contract
rhinoviru
infect
exposur
common
famili
group
children
bring
cold
home
school
opportun
transmiss
one
member
famili
anoth
high
two
larg
studi
dougla
et
al
hayden
et
al
shown
famili
one
member
alreadi
develop
cold
intranas
spray
time
per
day
effect
prevent
rhinoviru
cold
cold
due
virus
includ
coronaviru
parainfluenza
viru
infect
inhibit
yet
ifna
prepar
market
use
cold
perhap
benefit
seem
match
cost
suggest
mani
year
ago
failur
produc
ifn
acut
episod
influenza
may
contribut
death
overwhelm
pneumonia
baron
isaac
recent
shown
product
ifna
respons
influenza
viru
infect
may
genet
determin
haller
et
al
therapeut
use
ofifn
influenza
epidem
therefor
merit
studi
futur
antivir
anti
prolif
immunomodulatori
effect
ifn
good
choic
trial
patient
wart
result
drug
chronic
infect
one
mani
serotyp
human
papillomaviru
inde
ifn
prove
clinic
activ
viral
type
papillomaviru
wart
variou
type
appear
found
commonli
skin
occasion
genit
region
condyloma
acuminata
rare
larynx
laryng
papillomatosi
estim
new
case
juvenil
laryng
papillomatosi
jlp
annual
usa
first
papillomaviru
infect
ifn
treatment
tri
consid
first
initi
uncontrol
studi
suggest
leucocyt
ifn
treatment
benefici
children
jlp
firm
conclus
could
drawn
small
number
involv
gobel
et
al
goepfert
et
al
haglund
et
al
mccabe
clark
recent
larg
multicentr
control
trial
one
kashima
et
al
leventh
et
al
children
sever
jlp
enrol
iyear
crossov
studi
randomis
one
two
treatment
arm
patient
one
arm
receiv
iymphoblastoid
ifn
period
mum
daili
day
time
week
next
month
observ
next
month
arm
given
ifn
similarli
month
initi
observ
period
children
examin
endoscopi
everi
month
studi
papilloma
remov
surgic
result
show
patient
group
improv
significantli
receiv
ifn
antibodi
neutralis
ifn
detect
often
transient
serum
children
week
et
al
incid
much
higher
seen
categori
patient
treat
type
ofifn
antibodi
low
titr
appear
influenc
clinic
outcom
thurmond
et
al
mani
patient
continu
treatment
ifn
end
lyear
studi
period
put
back
treatment
four
year
later
patient
trace
initi
clinic
benefit
sustain
patient
complet
remiss
clinic
signific
partial
respons
leventh
et
ai
unpublish
data
anoth
studi
heali
et
ai
jlp
patient
randomli
assign
either
receiv
human
leucocyt
ifn
mum
daili
week
time
week
year
observ
surgeri
requir
report
papilloma
grew
significantli
slowli
first
month
ifntreat
group
observ
differ
diminish
second
month
spite
continu
ifn
administr
clear
whether
differ
durat
respons
larg
studi
reflect
ifn
dose
type
lymphoblastoid
versu
leucocyt
studi
design
report
annual
incid
genit
wart
recent
surv
ys
case
per
popul
sexual
transmit
diseas
incid
seem
increas
chuang
et
al
depart
health
social
secur
mani
treatment
use
includ
topic
applic
caustic
agent
like
podoph
yllin
podoph
yllumresin
trichloroacet
acid
physic
remov
visibl
lesion
cauteri
cryotherapi
laser
convent
surgeri
eskelinen
mashkilleyson
treatment
may
caus
pain
scar
system
toxic
recurr
rate
high
report
minor
patient
condyloma
resist
treatment
rapidli
recur
repres
difficult
manag
problem
appear
signific
proport
success
treat
ifna
prepar
although
treatm
ent
rel
expens
often
system
side
effect
earli
report
open
studi
suggest
condyloma
acuminata
respond
treatment
variou
type
ifn
ikic
et
ai
scott
csonka
observ
sinc
confirm
numer
randomis
doubleblind
placebocontrol
trial
ifna
prepar
human
cell
recombin
origin
comparison
result
differ
clinic
trial
difficult
mani
variabl
site
type
size
lesion
basi
patient
select
clinic
endpoint
chosen
type
ifn
use
dose
durat
treatment
also
rout
administr
explor
ifn
inject
either
directli
wart
intramuscularli
subcutan
remot
site
studi
intralesion
administr
prepar
recombin
eron
et
ai
hatch
vanc
et
ai
natur
ifna
friedrnankien
et
ai
geffen
et
ai
lesion
complet
resolv
patient
highest
rate
achiev
studi
leucocyt
ifn
friedmankien
et
ai
median
age
patient
year
median
number
wart
rang
factor
suggest
lesion
rel
recent
thu
unlik
refractori
treatment
intralesion
administr
initi
give
rel
high
local
concentr
ifn
inject
wart
occurr
usual
system
side
effectsshow
also
absorpt
site
whether
suffici
elimin
subclin
infect
elsewher
known
report
relaps
rate
friedmankien
et
ai
lack
respons
uninject
wart
geffen
et
ai
thu
theoret
ifn
given
system
may
advantag
efficaci
demonstr
number
studi
gall
et
ai
gall
et
ai
kirbi
et
ai
reichman
et
ai
week
et
ai
sever
studi
gall
et
ai
gall
et
ai
week
et
ai
iymphoblastoid
ifn
administ
combin
total
male
femal
longstand
refractori
condyloma
dose
rang
mum
mum
given
daili
day
time
week
week
overal
lesion
decreas
size
patient
mani
patient
result
accompani
usual
side
effect
ifn
dose
relat
consid
accept
patient
although
dose
reduc
treatment
stop
neutralis
antibodi
problem
recent
multicentr
studi
condylomata
intern
collabor
studi
group
benefit
seen
cours
patient
recurr
genit
andor
perian
condyloma
result
emphasis
need
work
defin
role
ifna
treatment
lesion
perhap
best
approach
includ
use
combin
therapi
exampl
laser
treatment
suggest
result
anoth
recent
trial
peterson
et
al
skin
wart
part
bodi
result
human
papillomaviru
infect
rel
common
small
proport
mani
patient
nongenit
wart
fail
respond
even
repeat
local
treatment
varieti
convent
agent
result
great
frustrat
patient
physician
alik
shown
number
studi
prepar
human
leucocyt
iymphoblastoid
recombin
ifna
benefici
patient
eg
eron
et
al
gibson
gibson
et
al
niimura
best
regimen
term
dose
rout
frequenc
administr
durat
treatment
remain
defin
experi
human
iymphoblastoid
ifn
suggest
intralesion
administr
advantag
rout
treatment
sever
persist
skin
wart
gibson
singl
inject
base
largest
troublesom
wart
week
week
gave
impress
rate
clearanc
patient
also
improv
nearbi
distant
wart
intralesion
inject
briefli
pain
extent
depend
site
involv
usual
mild
drug
influenzalik
side
effect
associ
treatment
dose
ifn
nevertheless
clinic
detect
local
tissu
damag
success
rate
rel
high
regimen
prove
accept
patient
involv
berman
et
al
report
mean
respons
treat
wart
patient
given
intralesion
inject
given
placebo
ifn
inhibit
growth
vitro
number
retrovirus
includ
hiv
ifna
produc
doserel
suppress
hiv
replic
peripher
blood
mononuclear
cell
vitro
physiolog
achiev
concentr
wherea
ifni
hartshorn
et
al
ho
et
al
yamamoto
et
al
howev
monocytemacrophag
cell
line
interferon
show
antihiv
activ
crespi
hartshorn
et
al
kornbluth
et
al
yamada
et
al
ifna
appear
affect
predominantli
later
stage
hiv
replic
notabl
viru
assembl
releas
ifna
treatment
hivinfect
cell
cultur
result
reduct
viru
releas
cultur
supernat
increas
cellassoci
virion
poli
et
al
remov
ifn
lead
releas
preassembl
virion
result
higher
concentr
cultur
never
treat
ifna
prolong
administr
would
seem
requir
control
hiv
replic
effect
given
encourag
vitro
result
appear
paradox
ifna
often
detect
sera
patient
advanc
hiv
diseas
buimovici
klein
et
al
de
stefano
et
al
eyster
et
al
ifn
unusu
predominantli
acidlabil
product
correl
declin
immun
statu
present
downregul
ifna
receptor
appear
occur
lead
decreas
respons
exogen
administ
ifn
phenomenon
seen
patient
kaposi
sarcoma
oettgen
et
al
vadhanraj
et
al
presenc
endogen
ifn
may
explain
lack
efficaci
toxic
first
studi
describ
studi
aid
patient
compar
differ
ifna
dose
time
weekli
placebo
fail
detect
differ
efficaci
toxic
variabl
treatment
period
interferon
alpha
studi
group
placebocontrol
studi
highdos
daili
ifna
week
patient
much
earlier
diseas
antivir
effect
note
term
number
patient
becom
hiv
cultureneg
lane
et
al
howev
high
dose
well
toler
one
studi
ifn
dose
daili
asymptomat
patient
show
reduct
antigen
marker
hiv
infect
toler
poor
borucki
et
al
pilot
studi
conduct
ifn
arc
aid
patient
produc
encourag
result
baron
et
al
pennington
et
al
overal
result
suggest
ifn
singl
agent
appropri
treatment
hivinfect
patient
natur
infect
requir
prolong
lifelong
therapi
ifna
ifnij
howev
shown
role
treat
subset
patient
aidsassoci
malign
kaposi
sarcoma
de
wit
et
al
mile
et
al
oettgen
et
al
vadhanraj
et
al
volberd
et
al
known
antiprolif
effect
ifn
combin
antihiv
activ
made
ideal
agent
tri
tumour
high
dose
mum
induc
respons
rate
patient
like
benefit
higher
count
patient
without
signific
hivassoci
symptom
strong
synergist
inhibit
hiv
vitro
combin
ifna
nucleosid
analogu
zidovudin
dideoxycytidin
hartshorn
et
al
vogt
et
al
william
colbi
zidovudin
dideoxycytidin
revers
transcriptas
inhibitor
act
earlier
stage
hiv
lifecycl
ifn
factor
may
account
synergist
activ
clinic
studi
ofifna
zidovudin
variou
dose
combin
conduct
patient
kaposi
sarcoma
bratzk
et
ai
fischl
et
ai
gustavo
et
al
kovac
et
al
krown
et
ai
mix
result
obtain
trial
tumour
respons
rate
vari
greater
higher
respons
rate
would
expect
ifn
alon
report
patient
low
count
fischl
et
al
krown
et
al
gener
higher
dose
combin
show
better
respons
less
well
toler
addit
myelotox
hepatotox
frequent
observ
commonli
dose
limit
coadministr
growth
factor
gmcsf
one
possibl
method
counteract
neutropenia
tripl
combin
investig
preliminari
result
indic
prevent
neutropenia
possibl
may
potenti
subject
side
effect
ifn
krown
et
al
perhap
greatest
potenti
combin
ifn
zidovudin
prove
earli
hiv
diseas
use
much
lower
dose
use
kaposi
sarcoma
preliminari
result
low
dose
ifna
zidovudin
daili
respect
patient
earli
hiv
diseas
shown
signific
reduct
antigen
lower
dose
well
toler
orholm
et
al
studi
lowdos
combin
compar
zidovudin
alon
way
hope
establish
role
combin
diseas
progress
summari
although
ifn
prove
use
treatment
kaposi
sarcoma
appear
role
singl
agent
treatment
hiv
diseas
perhap
greatest
valu
ifn
use
combin
antivir
agent
combin
use
zidovudin
ifna
appear
role
manag
patient
kaposi
sarcoma
although
optim
dose
maximum
antitumour
effect
minimum
toxic
remain
fulli
defin
valu
combin
treatment
earlier
manifest
hiv
diseas
remain
determin
although
individu
recov
complet
infect
hepadnaviru
hepat
b
hbv
becom
chronic
carrier
develop
chronic
activ
hepat
estim
million
carrier
total
worldwid
million
new
infect
annual
million
death
long
term
sequela
cirrhosi
primari
liver
cancer
treatment
thu
far
tri
chronic
hepat
b
use
ofifna
seem
promis
question
use
ifna
prepar
chronic
hepat
b
best
consid
relat
pathogenesi
clinic
cours
chronic
infect
typical
run
prolong
cours
man
year
follow
term
presenc
amount
variou
hbv
protein
patient
serum
surfac
antigen
hbsag
viru
dna
polymeras
core
protein
hbcag
socal
e
antigen
hbeag
deriv
core
protein
hull
mcgeoch
correspond
serum
antibodi
also
use
marker
follow
cours
infect
chronic
hepat
b
initi
phase
immun
toler
characteris
abund
viru
replic
liver
cell
serum
contain
high
level
hbeag
hbv
dna
dna
polymeras
littl
histolog
evid
liver
inflamm
biochem
abnorm
minim
paediatr
patient
phase
sinc
continu
hbv
replic
usual
seriou
late
consequ
discuss
logic
treat
antivir
agent
ifna
stage
ifna
may
also
help
break
immun
toler
occur
whether
spontan
result
treatment
cytotox
cell
recognis
viru
antigen
increas
level
hla
class
antigen
surdrug
face
infect
liver
cell
lyse
elimin
full
recoveri
infect
hbv
continu
replic
hepatocyt
turn
lyse
cell
progress
liver
damag
result
thu
prime
object
treatment
stop
hbv
replic
usual
monitor
term
loss
hbeag
marker
viru
replic
serum
sometim
follow
develop
antihb
antibodi
chang
associ
loss
biochem
marker
liver
inflamm
improv
liver
histolog
hoofnagl
et
al
liaw
et
al
perillo
et
al
realdi
et
al
suppress
viru
replic
also
reduc
infect
carrier
result
particularli
import
health
care
personnel
women
childbear
age
offspr
carrier
mother
hbeag
posit
becom
carrier
hepat
b
viru
contrast
born
hbeagneg
carrier
mother
oon
chronic
hbv
hepat
patient
especi
children
activ
hbv
replic
shown
high
serum
titr
hbeag
hbv
dna
liver
inflamm
whether
patient
defect
immun
respons
thu
protect
liver
damag
due
cours
develop
liver
diseas
yet
unknown
anoth
import
group
patient
neither
hbeag
antihbeag
antibodi
found
serum
yet
diseas
part
icularli
aggress
shown
liver
histopatholog
increasingli
therefor
clinic
progress
monitor
term
amount
circul
viru
measur
hbv
dna
hybridis
techniqu
loss
serum
dna
correl
well
disappear
hbcag
liver
cell
hsu
et
al
eddleston
person
commun
viru
replic
continu
shown
continu
presenc
hb
hbe
antigen
serum
liver
show
persist
histolog
evid
damag
progress
cirrhosi
like
within
period
half
patient
aldershvil
et
al
andr
et
al
chu
et
al
hadziyanni
et
al
lindh
et
al
sancheztapia
et
al
subject
persist
hb
antigenaemia
particularli
infect
earli
life
run
rel
risk
ultim
develop
primari
hepatocellular
carcinoma
phc
estim
time
greater
match
control
marker
diseas
beasley
hwang
tumour
usual
develop
year
primari
hbv
infect
although
occasion
much
sooner
subject
extens
cirrhosi
due
chronic
hepat
b
first
report
clinic
trial
variou
prepar
human
ifna
chronic
hepat
b
date
back
mani
year
desmyt
et
al
greenberg
et
al
result
earli
studi
review
scott
tyrrel
daili
inject
ifn
usual
led
rapid
drop
level
circul
hbv
dna
polymeras
viru
dna
although
return
patient
previou
even
somewhat
higher
level
treatment
stop
week
studi
treat
patient
appear
deriv
benefit
howev
studi
involv
patient
total
includ
control
group
show
level
spontan
impro
vement
absenc
ifn
treatment
definit
evid
ifna
treatment
gave
benefit
recent
result
publish
larg
number
control
trial
differ
ifna
prepar
use
gener
conclus
drawn
remarkabl
consist
respons
obtain
great
major
patient
show
initi
respons
ifna
treatment
almost
certainli
reflect
direct
antivir
effect
prepar
within
first
week
level
circul
hbv
dna
fall
see
fig
mani
patient
viru
dna
complet
clear
within
week
anderson
et
al
patient
dna
found
even
sensit
hybridis
assay
patient
also
lose
circul
hbeag
seroconvert
antihbeag
antibodi
posit
dusheiko
et
al
hoofnagl
et
al
perillo
et
al
seroconvers
typic
associ
mild
hepatitislik
ill
transient
rise
liver
enzym
episod
occur
consist
man
studi
week
treatment
suggest
consequ
spontan
event
seroconvers
follow
improv
liver
histolog
perillo
et
al
patient
go
clear
hbsag
blood
produc
antihb
antibodi
order
achiev
seroconvers
treatment
ifna
must
continu
month
longer
treatment
increas
seroconvers
rate
trial
low
dose
ifna
given
long
term
suppress
therapi
way
reliabl
result
avail
yet
dose
use
variou
trial
vari
wide
daili
yokosuka
et
al
perillo
et
al
found
dose
ifna
given
time
weekli
led
seroconvers
treat
wherea
dose
imu
effect
placebo
higher
dose
appear
give
better
result
dose
whole
well
toler
patient
develop
fever
malais
usual
first
inject
long
term
treatment
chronic
lethargi
depress
becom
problem
minor
patient
renault
et
al
term
criteria
choos
patient
treatment
consider
theoret
earlier
patient
success
treat
cours
diseas
lower
number
ofhepatocyt
contain
integr
hbv
sequenc
recent
trial
patient
clear
hbeag
hbsag
also
found
free
circul
hbv
dna
test
polymeras
chain
reaction
perillo
et
al
howev
earli
immun
toler
phase
chronic
hepat
b
viru
infect
characteris
low
serum
level
liver
enzym
level
best
guid
like
respons
ifna
therapi
high
level
serum
alanin
amino
transferas
alt
aspart
amino
transferas
ast
associ
increas
respons
rate
hoofnagl
et
al
perillo
et
al
therefor
suggest
patient
serum
alt
level
greater
twice
normal
treat
ifna
hoofnagl
thu
later
cours
diseas
patient
treat
ifna
like
respond
greater
likelihood
liver
damag
hepatocyt
contain
integr
hbv
dna
consequ
correspondingli
high
risk
later
develop
hepatocellular
carcinoma
choic
treat
ifna
must
therefor
made
balanc
likelihood
respons
insubstanti
cost
treatment
suggest
respons
ifna
less
asiat
patient
especi
children
caucasian
recent
studi
adult
male
chines
shown
benefit
liaw
et
al
patient
hiv
infect
respond
rel
poorli
medonald
et
al
success
ifna
treatment
clearli
simpl
reflect
antivir
effect
viru
elimin
follow
chang
balanc
host
immun
respons
natur
yet
understood
remain
problem
major
patient
clear
hbv
treat
ifna
perhap
antivir
effect
ifna
block
termin
portion
polymeras
protein
shown
vitro
foster
et
al
present
way
increas
respons
level
seen
clinic
trial
even
though
number
approach
tri
promis
appear
use
ifna
pretreat
steroid
earli
report
success
protocol
perillo
et
al
seem
confirm
later
studi
perillo
et
al
howev
result
recent
studi
yf
liaw
publish
suggest
regimen
inde
improv
result
certain
categori
patient
chines
children
treat
develop
rel
high
titr
neutralis
antibodi
found
less
like
respond
low
titr
antibodi
none
lok
lai
lok
et
al
note
itali
chronic
carrier
antibodi
hbe
serum
detect
hbeag
nearli
activ
diseas
characterist
sever
liver
patholog
even
though
hepatocyt
express
hbcag
within
period
histolog
pictur
chang
one
chronic
persist
hepat
chronic
activ
hepat
final
cirrhosi
patient
repres
anoth
categori
patient
urgent
need
treatment
benefit
ifn
treatment
best
assess
term
total
loss
ofhbv
dna
serum
alberti
colleagu
obtain
encourag
result
preliminari
trial
lymphoblastoid
ifn
patient
confirmatori
studi
urgent
need
summaris
good
rational
use
ifna
prepar
treat
patient
chronic
hepat
b
patient
expect
deriv
substanti
benefit
although
still
better
result
may
obtain
futur
use
combin
antivir
immunomodulatori
agent
ifna
prepar
use
present
best
treatment
avail
import
diseas
chronic
nona
nonb
nanb
hepat
may
also
progress
cirrhosi
ifn
prepar
test
patient
mani
patient
antibodi
recent
identifi
hepat
c
viru
least
seem
associ
infect
develop
primari
hepatocellular
carcinoma
earli
studi
short
ifna
cours
given
liver
transaminas
level
serum
normalis
treatment
soon
afterward
return
previou
elev
level
thompson
et
al
recent
studi
ifna
given
time
week
week
serum
alanin
aminotransferas
level
fell
normal
nearnorm
level
receiv
dose
imu
receiv
latter
group
improv
liver
histolog
regress
oflobular
periport
inflamm
treatment
cours
half
respond
relaps
davi
et
al
similar
trial
dose
given
time
week
month
patient
show
complet
respons
term
normal
geometr
mean
level
serum
ast
cours
treatment
normal
enzym
level
end
treatment
followup
month
sustain
respons
dibischeli
et
al
sever
studi
progress
higher
dose
ifna
given
longer
period
lymphoblastoid
ifn
given
time
weekli
dose
preliminari
result
show
respons
patient
sixteenth
week
treatment
jacyna
et
al
sinc
low
dose
employ
well
toler
consider
optim
ifna
becom
treatment
choic
import
diseas
inde
use
hepat
c
infect
alreadi
approv
number
countri
interferon
discov
seem
would
prove
success
treatment
viral
infect
antibiot
realm
bacteri
diseas
hope
disappoint
far
acut
viral
infect
concern
probabl
treatment
start
time
contrast
discuss
preced
section
ifna
prepar
prove
consider
valu
treatment
certain
chronic
viral
infect
affect
million
peopl
although
much
still
remain
learn
best
administ
condit
seem
doubt
year
come
ifna
use
benefit
increas
numb
er
patient
cal
respons
modifi
san
rerno
novemb
esculapio
bologna
pp
chu
